30-day average of 14 articles Β· scale β100 to +100
Across 14 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Boston Scientific news is Neutral (+1)
on a scale from β100 to +100.
That is up 9 points from the previous 30 days (-8).
π WATCHMAN FLX Pro trials show noninferiority with reduced bleeding risks.
π Global recalls for Neuromodulation discs and microcatheters create operational risks.
Slightly Bullish +15
Boston Scientific stock faces recall scrutiny across device lines
AI-generated analysis
Key insights
π Boston Scientific faces operational risks from multiple Class II recalls involving Neuromodulation therapy discs and Direxion Torqueable Microcatheters distributed globally.
β οΈ Quality control issues could lead to rework costs, regulatory scrutiny, and disruption in interventional and neuromodulation product lines.
π Recalls add pressure to the WATCHMAN and electrophysiology franchises which are already facing volume trends challenges.
π Recent trial results for the WATCHMAN FLX Pro device demonstrated noninferiority with reduced bleeding risks compared to dual antiplatelet therapy.
π Analysts project US$23.0 billion revenue and US$4.0 billion earnings by 2029 based on a 2.9% annual growth rate.
π Optimistic estimates suggest potential for US$24.4 billion revenue and US$4.4 billion earnings by 2029 if execution targets are met.
π€ The company's future performance depends on offsetting weaker franchises with its cardiovascular and MedSurg portfolios.
π° Strategic growth relies on successful restructuring savings and the integration of the planned Penumbra acquisition.
π Bullish signals
πRecent clinical trial results for the WATCHMAN FLX Pro device showed noninferiority for aspirin alone or reduced-dose NOAC regimens versus dual antiplatelet therapy at six months.
πThe findings from the WATCHMAN FLX Pro trials indicate similar ischemic stroke rates and less bleeding, which could support the franchise if left atrial appendage closure volumes stabilize.
π Risk factors
πMultiple Class II recalls reported in 2026 involving firmware problems in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters raise potential remediation costs.
πQuality control issues associated with recent recalls add operational risk to a portfolio already facing pressure in electrophysiology and WATCHMAN product lines.
Article
Boston Scientific faces renewed investor scrutiny following multiple voluntary Class II device recalls reported in 2026, specifically involving firmware issues in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters. These quality control incidents introduce operational risks regarding potential remediation costs, tighter regulatory oversight, and possible disruption to the company's interventional and neuromodulation product lines.
The analysis highlights that these recall risks compound existing pressures within the WATCHMAN and electrophysiology franchises. While Simply Wall St notes that recent trial results for the WATCHMAN FLX Pro device show promising noninferiority outcomes, the broader investment case remains contingent on the company's cardiovascular and MedSurg portfolios offsetting weaker performance in specific areas.
Analysts project Boston Scientific to generate US$23.0 billion in revenue and US$4.0 billion in earnings by 2029, with more optimistic estimates reaching US$24.4 billion in revenue and US$4.4 billion in earnings. These long-term forecasts depend heavily on successful product quality maintenance, supply reliability, and the integration of the planned Penumbra acquisition to sustain growth.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Boston Scientific (NYSE:BSX) demonstrates strong financial performance with earnings per share growing 60% annually over the last three years, a metric often favored by long-term investors as it correlates with share price appreciation. Despite this high growth rate rarely lasting indefinitely, the company's consistency in generating revenue and profit is highlighted as a positive fundamental trait that distinguishes it from "story stocks" that lack profitability. Revenue grew 17% to reach US$21 billion during the reported period, while EBIT margins remained stable, indicating operational efficiency despite the scale of expansion.
Insider alignment with shareholders is confirmed through significant management investment; insiders hold a stake valued at US$158 million, representing 0.2% of the total business valuation of approximately US$84 billion. Although this ownership percentage is small relative to the company's massive size, it serves as evidence that leadership is financially committed to the stock's performance and shares risk with external investors. The article suggests Boston Scientific may be approaching an inflection point where rapid earnings growth attracts further investment interest.
The content concludes by recommending a closer examination of valuation metrics, specifically noting that while the quality of earnings and insider confidence are strong, investors should also check the price-to-earnings ratio relative to industry standards before adding the stock to their watchlist or portfolio. The analysis relies on historical data and forecasts rather than serving as direct financial advice, emphasizing fundamental long-term value driven by consistent profitability and insider skin-in-the-game.
π Boston Scientific shows strong 60% annual EPS growth and $21B revenue.
π§ AI will transform healthcare, with insiders holding ~$158M stake in the firm.
β οΈ Analysts caution that rapid growth may not last without a valuation check.
π Investors are warned against chasing 'story stocks' with no revenue or profit, cautioning that loss-making companies can act like a sponge for capital.
π‘ For investors preferring companies that generate revenue and profits, Boston Scientific (NYSE:BSX) is presented as a strong candidate.
π Boston Scientific has increased its earnings per share (EPS) by an average of 60% per year over the last three years.
π While EPS growth is high, analysts note that such rapid growth rarely lasts long and should be monitored closely.
π° The company reported revenue growth of 17% to reach US$21 billion for the latest period.
βοΈ Earnings Before Interest and Tax (EBIT) margins have remained fairly unchanged over the last year.
π§ AI is identified as a key technology set to transform healthcare, though specific Boston Scientific products in this area were not detailed.
πΌ Company insiders hold a stake worth approximately US$158 million in Boston Scientific.
π₯ Insider ownership represents only 0.2% of the total business, which reflects the company's massive market capitalization of around US$84 billion.
π The alignment between management and shareholders is viewed positively due to insiders having significant financial 'skin in the game'.
π Analysts suggest that fast EPS growth can indicate an inflection point in a business, creating potential investment opportunities.
π A free interactive visualization of Boston Scientific's forecast profits is available for further analysis.
π° While quality earnings are noted, the article advises checking if the stock trades at a high or low P/E relative to its industry.
β οΈ This specific analysis focuses on earning quality and insider confidence but has not yet calculated the intrinsic value of the stock.
π A list of other US companies with promising growth potential and insider confidence is offered for further exploration.
π Readers are reminded that reportable insider transactions discussed refer only to relevant jurisdiction filings.
βοΈ This analysis by Simply Wall St is based on historical data and unbiased methodology but does not constitute financial advice.
β The article explicitly states it is not a recommendation to buy or sell any stock.
π§ Analysis may not factor in the latest price-sensitive announcements or qualitative material released after publication.
β οΈ Investors are advised that the analysis does not account for individual objectives or specific financial situations.
π Information regarding consumer health privacy policies and editorial contact details is provided at the end of the article.
Bullish Signals
EPS grew 60% annually over three years.
Revenue rose 17% to reach $21b.
Management invested $158m showing alignment.
Insiders hold stakes in $84b cap co.
Risk Factors
Chasing 'story stocks' without revenue or profit risks losing capital.
High EPS growth rates at Boston Scientific rarely last long.
Insider stake of 0.2% indicates limited alignment with shareholders.
Valuation risk remains unaddressed regarding high or low P/E.
Analysis ignores recent price-sensitive announcements creating information lag.
Bullish Signals
Boston Scientific achieved impressive earnings per share (EPS) growth of 60% per year over the last three years.
The company reported strong revenue growth of 17%, reaching a total of US$21b for the period.
Management holds significant skin in the game with an investment valued at US$158m, demonstrating alignment with shareholder interests.
Despite being a large US$84b market capitalization company, insiders maintain a stake that suggests confidence in future performance.
Risk Factors
The article warns against chasing 'story stocks' without revenue or profit, suggesting investors should be cautious of throwing money at companies that are merely losing capital.
While Boston Scientific has shown strong recent growth, the text explicitly states that such high EPS growth rates rarely last long, indicating a potential future slowdown.
EBIT margins remained unchanged over the last year despite revenue growth, suggesting that the company is not improving its efficiency or profitability at the operating level.
Insiders hold a stake worth US$158m, but this represents only 0.2% of the business, which may indicate limited alignment compared to larger stakes.
The analysis has not yet determined if Boston Scientific is trading at a high P/E or low P/E relative to its industry, leaving valuation risk unaddressed.
The article notes that their analysis does not factor in the latest price-sensitive company announcements or qualitative material, creating potential information lag.
The article is not worth deleting because BSX (Boston Scientific) and CELC (Celcuity) are the central focus of the report, with specific financial data and analyst opinions provided for both. The text explicitly details new Buy ratings and price targets assigned by analysts from major firms like Needham and Barclays. For Boston Scientific, Matt Miksic of Barclays issued a Buy rating on May 5 with a price target of $96.00, which is significantly higher than the share's closing price of $56.50 at the time. This suggests an implied upside for the stock based on the analyst's projection.
Regarding Celcuity, Gil Blum from Needham maintained a Buy rating with a price target of $157.00 against a closing price of $125.65. The article notes that Celcuity recently reported positive Phase 3 trial results for its drug gedatolisib in the VIKTORIA-1 study, which appears to be the primary catalyst driving the analyst's bullish sentiment. The text also references broader market consensus from sources like TipRanks, indicating a Strong Buy rating for Boston Scientific with an average price target of $90.00 and for Celcuity with a target of $136.00.
Although the content includes some promotional material from TipRanks and generic commentary on the healthcare sector or market trends, these elements serve to frame the specific news about the two tickers rather than dominate the narrative. The core value of the article lies in the concrete analyst ratings, price targets, and the mention of clinical trial success for Celcuity, making it a relevant piece for investors tracking BSX or CELC.
β Celcuity sees analyst Buy rating maintained with a $157 price target.
π₯ Street consensus rates Celcuity as Strong Buy following positive Phase 3 data.
π° Boston Scientific holds Strong Buy consensus with a projected upside of 55%.
π Analyst Gil Blum from Needham maintained a Buy rating on Celcuity (CELC) with a price target of $157.00.
π° Celcuity shares closed last Friday at $125.65, representing significant potential upside based on the new price target.
β The analyst is rated 5-stars by TipRanks with an average return of 11.7% and a 41.0% success rate.
π Street consensus for Celcuity suggests a Strong Buy rating with an average price target of $136.00.
β A previous report from April 19 reiterated a Buy rating on Celcuity with a $137.00 price target.
π Boston Scientific (BSX) received a Buy rating from analyst Matt Miksic at Barclays with a price target of $96.00.
π Miksic is rated as a 3-star analyst by TipRanks with an average return of 1.8% and a 49.2% success rate.
π₯ Analyst consensus for Boston Scientific currently leans toward a Strong Buy rating with an average target of $90.00.
π This consensus implies a potential 55.4% upside from current stock levels based on the average analyst price target.
πΌ A recent upgrade to Buy with a $72.00 target was issued by PerPlexity for Boston Scientific on April 23.
𧬠Celcuity reported positive Phase 3 results for its VIKTORIA-1 trial which achieved its primary endpoint.
π The positive trial results and competitive profile are driving the upward revision of the price target to $165.
π¬ Blum focuses his healthcare coverage on stocks including Artiva Biotherapeutics, Recursion Pharmaceuticals, and Mereo Biopharma.
Needham and Barclays maintain strong Buy ratings on Boston Scientific.
Barca's price target implies 55.4% upside potential for Boston Scientific.
Street consensus suggests Strong Buy with an average $90.00 target.
Gil Blum offers credible outlook with 11.7% average analyst return.
Celcuity receives 12.4% upside potential from its current valuation.
Risk Factors
Average $90 target lags recent upgrades, signaling analyst skepticism.
Barclay's Matt Miksic has low track record with 1.8% avg return.
Miksic's 49.2% success rate questions reliability of his bullish rating.
Divergent analyst opinions may indicate uncertainty about full stock upside.
Bullish Signals
Analysts Gil Blum from Needham and Matt Miksic from Barclays both maintained strong Buy ratings on Boston Scientific, signaling robust institutional confidence in the company's performance.
Matt Miksic's price target of $96.00 for Boston Scientific implies a significant 55.4% upside potential from its current trading levels, suggesting substantial growth opportunity.
The general street consensus suggests a Strong Buy rating for Boston Scientific with an average price target of $90.00, reinforcing the bullish sentiment among major market participants.
Analyst Gil Blum has a proven track record as a 5-star analyst with an impressive 41.0% success rate and an average return of 11.7%, lending credibility to the positive outlook for Celcuity.
Celcuity received a $136.00 average price target from analysts, representing a 12.4% upside from current levels, which indicates a favorable valuation perspective.
Risk Factors
Boston Scientific's average price target of $90.00 lags significantly behind recent upgrades from other firms, such as a $72.00 target from TipRanks β PerPlexity, potentially indicating divergent analyst opinions or skepticism about the full upside.
Analyst Matt Miksic of Barclays has a relatively low historical track record with an average return of only 1.8% and a 49.2% success rate, which may introduce uncertainty regarding the reliability of his bullish rating and $96.00 price target for Boston Scientific.
Boston Scientific's fair value estimate has been adjusted from US$104.24 to US$102.00 by Simply Wall St, a change that aligns with a broader trend of price target resets across the financial community. While major banks such as Citi, Goldman Sachs, UBS, and Canaccord have maintained their Buy ratings, many institutions including JPMorgan, Wells Fargo, Mizuho, and Stifel have reduced their price targets by double-digit dollar amounts. This divergence suggests that while analyst sentiment remains largely positive regarding the company's long-term growth story, expectations for immediate growth metrics, margins, or execution risks are being recalibrated to a more conservative level. Evercore ISI has added the stock to its Tactical Outperform list, indicating confidence in current execution and valuation assumptions despite the general trimming of targets. Additionally, Boston Scientific has been removed from premium research lists such as BofA's US 1 List and Citi's Focus List, signaling that some analysts no longer view the stock as a top priority within their MedTech coverage.
The company provided specific guidance for fiscal quarters and full year 2026, projecting net sales growth of approximately 10.5% to 12.0% on a reported basis and 8.5% to 10.0% on an organic basis for the first quarter, excluding foreign exchange and certain acquisition and divestiture impacts. For the full year 2026, Boston Scientific guided to estimated net sales growth of about 10.5% to 11.5% reported and 10.0% to 11.0% organic. Regarding share repurchases, the company reported no buybacks between October 1, 2025, and December 31, 2025, keeping the disclosed cumulative total at zero shares for US$0 million.
In valuation models associated with these shifts, revenue growth assumptions were eased from 10.52% to 10.41%, while net profit margin assumptions increased slightly from 19.08% to 19.14%. The future P/E multiple was reduced from 37.95x to 37.15x, and the discount rate was updated minimally from 7.94% to 7.95%. Beyond financial metrics, regulatory and product issues continue to surface in the narrative; FDA inspectors identified battery issues in certain Boston Scientific pacemakers, a finding referenced in a New York Times report regarding device performance inspections.
Future narratives surrounding Boston Scientific will likely focus on how its therapies, such as FARAPULSE and WATCHMAN, along with acquisitions like Axonics and Silk Road, expand its reach in cardiac and neuromodulation markets. Analysts and investors are also monitoring the role of emerging markets growth, ambulatory surgery center procedure volumes, and efficiency programs in supporting revenue diversification and margins. Key risks highlighted include tariffs, reimbursement changes, integration challenges from recent deals, and rising competition from lower cost device manufacturers in endoscopy, urology, and MedSurg segments.
π Analysts lowered price targets while maintaining mostly Buy ratings despite FDA battery concerns.
π Strategic focus remains on new therapies and emerging market diversification amid risks.
π Boston Scientific's fair value estimate was adjusted downward from US$104.24 to US$102.00, aligning with recent analyst target resets.
π Analysts are tightening growth and execution assumptions rather than questioning the core business model or making sweeping changes.
π¦ Major banks like Citi, Goldman Sachs, and UBS maintained Buy ratings while revising their models to reflect conservative expectations.
π Evercore ISI added BSX to its Tactical Outperform list, signaling confidence in performance based on current execution and valuation.
β¬οΈ A broad group of institutions, including JPMorgan and Wells Fargo, cut price targets by double-digit dollar amounts.
π·οΈ Some firms removed Boston Scientific from premium lists such as BofA's US 1 List and Citi's Focus List, downgrading its status despite positive ratings.
β οΈ FDA inspectors identified battery issues in certain pacemakers, according to a New York Times report referencing inspection findings.
πΌ For Q1 2026, Boston Scientific projected net sales growth of 10.5%β12.0% reported and 8.5%β10.0% organic.
π For full-year 2026, the company guided to 10.5%β11.5% reported growth and 10.0%β11.0% organic sales increase.
π« No share repurchases were made between October 1, 2025, and December 31, 2025, under the buyback program.
π Revenue growth assumptions in valuation models were eased slightly from 10.52% to 10.41%.
π° Net profit margin assumptions were adjusted upward marginally from 19.08% to 19.14%.
π The future P/E multiple assumption decreased from 37.95x to 37.15x in the valuation model.
π Discount rate updated from 7.94% to 7.95% reflects slight conservatism in the financial model.
π New therapies like FARAPULSE and WATCHMAN are expanding reach in cardiac and neuromodulation markets via acquisitions like Axonics.
βοΈ Risks include tariffs, reimbursement changes, integration challenges, and competition from lower-cost device manufacturers.
π Emerging market growth and ambulatory surgery center volumes are expected to support revenue diversification and margins.
π This analysis is general in nature, based on historical data and analyst forecasts, and does not constitute financial advice.
Bullish Signals
Major banks like Citi and Goldman maintain Buy ratings on Boston Scientific.
Evercore ISI added stock to its Tactical Outperform list.
Q1 2026 guidance shows net sales growth of 10.5% to 12.0%.
Full year 2026 targets net sales growth of 10.5% to 11.5%.
Therapies like FARAPULSE and WATCHMAN enable positive market expansion.
Risk Factors
Analysts cut price targets by double-digit dollar amounts.
Boston Scientific removed from premium analyst lists.
Fair Value estimate trimmed from $104.24 to $102.00.
FDA found battery issues in certain pacemakers.
Company reported zero share buybacks from Oct-Dec 2025.
Revenue growth assumptions eased from 10.52% to 10.41%.
Key risks include tariffs, reimbursement changes, and competition.
Bullish Signals
Several major investment banks including Citi, Goldman Sachs, UBS, and Canaccord have maintained Buy ratings on Boston Scientific despite revisions to their price targets, signaling continued confidence in the company's long-term growth story.
Evercore ISI added Boston Scientific to its Tactical Outperform list, indicating analysts see potential for shares to perform well based on current execution and valuation assumptions.
Boston Scientific issued strong first quarter 2026 guidance with estimated net sales growth of about 10.5% to 12.0% on a reported basis and 8.5% to 10.0% on an organic basis.
For full year 2026, the company guided to estimated net sales growth of about 10.5% to 11.5% reported and 10.0% to 11.0% organic, demonstrating sustained demand across key markets.
The article highlights positive expansion opportunities through therapies like FARAPULSE and WATCHMAN, which extend the company's reach across cardiac and neuromodulation markets.
Strategic acquisitions such as Axonics and Silk Road are positioned to expand Boston Scientific's market presence in critical therapeutic areas.
Risk Factors
Analysts have cut price targets by double digit dollar amounts, reflecting more conservative expectations around growth or execution risk.
Boston Scientific was removed from premium lists like BofA's US 1 List and Citi's Focus List, suggesting analysts no longer view it as a top idea in MedTech coverage.
The Fair Value estimate was trimmed from US$104.24 to US$102.00, indicating a downward adjustment in valuation by major analysts.
FDA inspectors identified battery issues in certain pacemakers, raising product safety and reputation concerns.
From 1 October 2025 to 31 December 2025, Boston Scientific reported no share repurchases, keeping cumulative total buybacks at 0 shares for US$0 million.
Revenue growth assumptions have been eased from 10.52% to 10.41% in valuation models, signaling a lower expected growth rate.
Key risks include tariffs, reimbursement changes, integration challenges from recent acquisitions, and rising competition from lower cost device manufacturers.
Smith & Nephew plc is identified as the better value option compared to Boston Scientific Corporation based on Zacks Investment Research analysis. The primary differentiator noted is the earnings estimate revision trend, which gives Smith & Nephew a Zacks Rank of #2 (Buy) versus a Rank of #4 (Sell) for Boston Scientific, indicating a more positive analyst outlook for SNN. This assessment is supported by specific valuation metrics where Smith & Nephew displays superior value characteristics; it boasts a forward price-to-earnings ratio of 13.52 compared to Boston Scientific's 16.84, and a lower price-to-book ratio of 2.48 versus 3.24. Additionally, the price-to-earnings-to-growth ratio for Smith & Nephew stands at 0.96, while Boston Scientific is at 1.04. These combined metrics contribute to Smith & Nephew receiving an A grade in the Value category of the Style Scores system, whereas Boston Scientific receives a C grade, leading analysts to conclude that Smith & Nephew is the superior choice for value investors currently.
π SNN earns a Buy rating due to strong earnings estimate revisions.
βοΈ SNN offers better value with lower forward P/E and PEG ratios.
π‘ Analysts view Smith & Nephew as the superior investment choice now.
π Smith & Nephew (SNN) receives a #2 (Buy) Zacks Rank due to strong earnings estimate revision trends.
πΉ Boston Scientific (BSX) currently holds a #4 (Sell) Zacks Rank, indicating weaker analyst outlook improvements.
βοΈ SNN carries a forward P/E ratio of 13.52 compared to BSX's higher rate of 16.84.
π The Price/Earnings-to-Growth (PEG) ratio for SNN is 0.96 versus 1.04 for Boston Scientific.
π¦ Smith & Nephew trades at a Price/Book value of 2.48, while Boston Scientific stands at 3.24.
π Based on these metrics, SNN earns an A grade in the Value category of Style Scores.
β οΈ Boston Scientific receives a lower C grade within the same Value style scoring system.
π‘ Analysts conclude that Smith & Nephew represents the superior value option right now.
π₯ Both companies operate within the Medical Products sector as well-known equities in this space.
High forward P/E of 16.84 suggests overvaluation vs peers.
Elevated P/B ratio of 3.24 exceeds underlying asset value.
Value grade C reflects weaker valuation fundamentals.
Bullish Signals
Smith & Nephew (SNN) holds a superior Zacks Rank of #2 (Buy), indicating more impressive earnings estimate revision trends compared to Boston Scientific.
SNN carries a Value grade of A versus BSX's C, based on favorable metrics like a lower forward P/E ratio of 13.52 and a PEG ratio of 0.96.
Risk Factors
Boston Scientific currently holds a Zacks Rank of #4 (Sell), indicating negative earnings estimate revision trends compared to competitors.
BSX carries a significantly higher forward P/E ratio of 16.84 versus Smith & Nephew's 13.52, suggesting it may be overvalued relative to peers.
The company's Price-to-Book (P/B) ratio is elevated at 3.24 compared to SNN's 2.48, raising concerns about whether the market value exceeds the underlying asset value.
BSX receives a Value grade of C from the Style Scores system, reflecting weaker valuation fundamentals and financial traits.
Faruqi & Faruqi, LLP has issued a shareholder reminder regarding a potential securities class action against Boston Scientific Corporation (NYSE: BSX), urging investors to contact the firm before May 4, 2026. The firm is investigating allegations that the Company and its executives violated federal securities laws by making false or misleading statements and failing to disclose critical information about the true state of Boston Scientific's U.S. EP (Electrophysiology) segment. Specifically, the complaint claims management knew the segment's growth rate was unsustainable and approaching a tipping point earlier than anticipated by the market, yet provided confidence-inspiring statements that misled investors and analysts.
The legal action stems from financial disclosures made on February 4, 2026, when Boston Scientific released its fourth quarter and full year 2025 results, revealing a significant disappointment in U.S. EP sales and issuing guidance for fiscal 2026 that fell well below expectations. Although the company attributed these poor results to slower-than-expected market growth and increased competition, investors argue this contradicted previous management assertions of a "growing" EP business and a strong understanding of competitive threats. Upon the announcement of these disappointing results, Boston Scientific's stock price dropped $16.12, representing a 17.6% decline to close at $75.50 per share on February 4, 2026, which the firm states caused financial injury to shareholders.
The notice highlights that May 4, 2026, is the deadline for investors to seek the role of lead plaintiff in the federal class action filed against the company. According to the filing, the court-appointed lead plaintiff must be an investor with the largest financial interest who directs and oversees litigation on behalf of the class; however, any member of the putative class may move the court to serve as lead plaintiff through counsel of their choice or remain an absent class member without affecting their ability to share in any recovery. The law firm has also encouraged anyone with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to contact them directly for potential whistleblower claims.
Investors affected are urged to have purchased or acquired securities in Boston Scientific between July 23, 2025, and February 3, 2026, and may discuss their options by contacting Partner James (Josh) Wilson at Faruqi & Faruqi, LLP via phone at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm, which has recovered hundreds of millions for investors since its founding in 1995 and maintains offices in New York, Pennsylvania, California, and Georgia, directs further inquiries to their website at www.faruqilaw.com/BSX or via their LinkedIn, X, and Facebook channels for updates.
ποΈ Shareholders must request lead plaintiff status by May 4, 2026.
βοΈ Executives face allegations of misleading statements about unsustained U.S. EP growth.
πΈ Stock fell 17.6% after missing earnings and issuing weak guidance.
ποΈ Investors can choose to lead the suit or remain passive class members.
π Faruqi & Faruqi, LLP is reminding Boston Scientific (BSX) shareholders of the May 4, 2026 deadline to request a role as lead plaintiff in a federal securities class action.
π’ The law firm alleges that BSX executives violated federal securities laws by making false or misleading statements regarding the company's U.S. EP segment.
β οΈ The complaint claims management knew the segment's growth was unsustainable and was approaching a tipping point earlier than anticipated.
π Investors and analysts were left surprised when BSX reported a net income miss and issued underwhelming guidance for the first half of fiscal 2026.
ποΈ On February 4, 2026, Boston Scientific published results showing disappointment in U.S. EP sales and guidance that fell below market expectations.
π¬ The company attributed its poor performance to slower-than-expected market growth and increased competition, contradicting prior claims of a "growing" business.
π Following the negative news, BSX's stock price dropped $16.12 (a 17.6% decline) to close at $75.50 per share on February 4, 2026.
βοΈ Becoming a lead plaintiff involves serving as the investor with the largest financial interest in the relief sought and directing the litigation on behalf of the class.
π₯ Shareholders may choose to serve as lead plaintiff, remain an absent member, or do nothing without affecting their ability to share in any recovery.
π° Faruqi & Faruqi states it has recovered hundreds of millions of dollars for investors since its founding in 1995 across multiple offices.
π Investors suffering losses are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss options.
π The firm also invites individuals with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to contact them.
πΌ This press release is classified as attorney advertising by Faruqi & Faruqi, LLP with prior results not guaranteeing similar outcomes.
Bullish Signals
No positive elements were found in this article as it is entirely a legal shareholder reminder regarding a securities class action, negative stock performance, and alleged misleading statements.
The law firm of Faruqi & Faruqi has recovered hundreds of millions of dollars for investors since its founding in 1995, demonstrating strong litigation track record.
Risk Factors
Boston Scientific (BSX) faced a significant stock price decline of $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, following the disclosure of disappointing results.
The company's net income missed expectations and issued underwhelming guidance for fiscal 2026, contradicting previous assertions of confidence in a 'growing' U.S. EP business.
Management's growth forecasts were proven unsustainable as the U.S. EP segment approached an earlier tipping point than anticipated by the market, leading to concerns over competitive pressures and slower market growth.
The securities class action alleges that executives violated federal securities laws by making false or misleading statements and failing to disclose the true state of the U.S. EP segment before February 4, 2026.
Investors who purchased securities between July 23, 2025, and February 3, 2026, suffered financial losses due to the company's failure to meet performance metrics and guidance targets.
On April 30, 2026, Pomerantz LLP issued an investor alert regarding a class action lawsuit filed against Boston Scientific Corporation (NYSE: BSX). The law firm represents investors who allege that the company, along with certain officers and directors, engaged in securities fraud or other unlawful business practices. Investors who experienced losses on their investment in Boston Scientific during the specified "Class Period" are advised to contact Danielle Peyton at 646-581-9980, 888.4-POMLAW (ext. 7980), or via email with their mailing address, telephone number, and the number of shares purchased to inquire about the lawsuit.
The central issue of the litigation concerns whether misconduct occurred that could warrant investor compensation. The class period is linked to specific negative market events: on February 4, 2026, Boston Scientific released its fourth-quarter 2025 financial results, which revealed lower-than-expected sales in its electrophysiology division. Following this release, the company issued guidance for fiscal year 2026 that fell well short of analyst expectations. Management attributed these underwhelming results to slower-than-anticipated market growth and increased competition. Consequently, the stock price dropped by $16.12 per share, representing a 17.6% decline, closing at $75.50 on February 4, 2026.
Investors have until May 4, 2026, to request that the court appoint them as Lead Plaintiff for the class action if they acquired Boston Scientific securities during the relevant period. A copy of the Complaint is available at www.pomerantzlaw.com, and further information regarding joining the suit can be found on the firm's website. Pomerantz LLP, founded by the late Abraham L. Pomerantz, describes itself as a premier firm in corporate and securities litigation with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. The firm notes it has recovered numerous multimillion-dollar damages awards for class members but includes standard legal disclaimers stating that prior results do not guarantee similar outcomes.
βοΈ Pomerantz Law filed a securities fraud class action against Boston Scientific.
π Lawsuit links stock drop to Q4 2025 earnings misses and poor guidance.
π Shareholders may become Lead Plaintiff by May 4, 2026, at the firm's contact details.
β οΈ Pomerantz Law Firm announced a class action lawsuit filed against Boston Scientific Corporation (NYSE: BSX).
π The legal complaint alleges securities fraud or other unlawful business practices involving the company's officers and directors.
π Investors have until May 4, 2026, to request appointment as Lead Plaintiff for the class action if they held shares during the relevant Class Period.
π Interested parties are advised to contact Danielle Peyton via phone at 646-581-9980 or via email using an provided protected address.
π§ When contacting the firm via email, investors should include their mailing address, telephone number, and the number of shares purchased.
π The full text of the Complaint is available for review at www.pomerantzlaw.com.
π The lawsuit concerns Boston Scientific's fourth quarter 2025 financial results released on February 4, 2026.
π Those earnings showed lower-than-expected sales specifically in the electrophysiology division.
β οΈ Management issued fiscal year 2026 guidance that fell significantly short of analyst expectations.
π The company attributed these negative results to slower market growth and increased competition.
π Following the earnings announcement, Boston Scientific's stock price dropped $16.12 per share on February 4, 2026.
π The share price decline represented a 17.6% drop, closing at $75.50 per share on that date.
βοΈ Pomerantz LLP is described as a premier firm specializing in corporate, securities, and antitrust class litigation.
π The law firm notes it has recovered numerous multimillion-dollar damages awards for previous class members.
β οΈ The press release includes standard attorney advertising disclosures stating prior results do not guarantee similar outcomes.
Risk Factors
A class action lawsuit has been filed against Boston Scientific Corporation alleging securities fraud or other unlawful business practices by the company and its officers/directors.
Boston Scientific reported lower-than-expected sales in its electrophysiology division for the fourth quarter of 2025.
The company issued fiscal year 2026 guidance that fell well short of analyst expectations, citing slower market growth and increased competition.
Following these disappointing results, Boston Scientific's stock price plummeted 17.6% to close at $75.50 per share on February 4, 2026.
Boston Scientific Corporation (NYSE:BSX) announced on March 30 that it has received FDA 510(k) clearance for its Asurys Fluid Management System, a new technology designed to manage irrigation and distention during endoscopic urologic procedures. The system is intended for use in ureteroscopy, cystoscopy, percutaneous nephrolithotomy (PCNL), and benign prostatic hyperplasia (BPH) treatments. By providing a single irrigation management solution, the device aims to streamline clinical workflows and assist in the diagnosis and treatment of conditions such as kidney stones. A primary feature of the Asurys System is its ability to regulate irrigation inflow to help maintain low intrarenal pressure (IRP) while ensuring clear visualization. When paired with the LithoVue Elite Single-Use Digital Flexible Ureteroscope, the system can automatically respond to IRP data in real-time.
This capability is designed to help physicians minimize the risk of exceeding pre-set pressure settings, which is critical for avoiding post-operative complications like sepsis or renal damage. The system also integrates irrigation control directly onto the scope handle, allowing physicians to activate an on-demand flush feature to reposition stones without manual assistance. Boston Scientific Corporation, incorporated in 1979, is a healthcare company that specializes in medical devices for interventional medical specialties, with segments including MedSurg and Cardiovascular. The FDA clearance enables the broader adoption of this technology in procedures where managing fluid levels is crucial for patient safety and procedural efficiency.
The article also contains commentary suggesting Boston Scientific could be among the 10 best growth stocks to buy for the next decade, though it notes that certain AI stocks may offer greater upside potential and less downside risk. It further references a free report on undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend. Additionally, the text includes a call to action to read related content titled "33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy." A disclosure states there is no conflict of interest, and readers are invited to follow Insider Monkey on Google News or sign in to access their portfolio.
π FDA clearance granted for new Asurys Fluid Management System on March 30.
β οΈ Maintaining low pressure is critical to avoiding post-operative complications such as sepsis or renal damage during kidney stone treatments.
π€ The system integrates irrigation control directly onto the scope handle to allow physicians to activate an on-demand flush feature for repositioning stones.
π’ Boston Scientific, incorporated in 1979, specializes in medical devices across MedSurg and Cardiovascular segments.
π The article notes BSX as a top growth stock but suggests certain AI stocks may offer greater upside potential with less downside risk.
π‘ The new technology aims to streamline clinical workflows while assisting in the diagnosis and treatment of conditions like kidney stones.
Bullish Signals
Boston Scientific ranked among 10 Best Growth Stocks for Next Decade.
FDA approved Asurys Fluid Management System on March 30.
New system streamlines kidney stone and BPH treatment workflows.
Irrigation control minimizes risks like sepsis or renal damage.
MedSurg segment benefits from direct irrigation integration.
Company maintains top growth status since 1979 incorporation.
Risk Factors
BSX faces lower upside than other AI stocks.
BSX isn't undervalued despite 'Top 10' label.
No financial metrics support growth stock claim.
BSX trails tech peers in investment outlook.
BSX lacks strong investor sentiment vs Cathie Wood.
Bullish Signals
Boston Scientific (NYSE:BSX) was ranked among the 10 Best Growth Stocks to Buy for the Next Decade, highlighting strong long-term growth potential.
On March 30, Boston Scientific received FDA 510(k) clearance for its new Asurys Fluid Management System, a significant regulatory milestone that expands its medical device portfolio.
The Asurys System is designed to streamline clinical workflows while assisting in the diagnosis and treatment of kidney stones and BPH treatments across multiple urologic procedures.
A key feature of the system is its ability to regulate irrigation inflow to maintain low intrarenal pressure (IRP), which helps minimize the risk of post-operative complications like sepsis or renal damage.
The integration of real-time automatic response to IRP data when paired with the LithoVue Elite Ureteroscope offers a competitive technological advantage for physicians.
Boston Scientific's MedSurg segment will benefit directly from this new technology as the system integrates irrigation control directly onto the scope handle.
While some analysts note AI stocks may offer different upside potential, Boston Scientific remains positioned as one of the top growth stocks with established market presence since its incorporation in 1979.
Risk Factors
Article explicitly states that other AI stocks offer greater upside potential and carry less downside risk than Boston Scientific.
The article suggests BSX may not be an undervalued investment despite the bullish 'Top 10' designation.
There are no specific financial metrics, earnings growth figures, or market cap expansions provided to substantiate the growth stock claim.
Comparison to AI stocks implies Boston Scientific is trailing technologically advanced peers in the near-term investment outlook.
Recommendation to explore Cathie Wood's portfolio instead suggests BSX lacks similar strong investor sentiment.
Boston Scientific (BSX) has experienced a significant share price decline over the past year, dropping approximately 31.8% from its previous high, with more recent drops of 34.7% year to date and 13.3% in the last month. Despite this sharp pullback, some investors are reassessing the stock's attractiveness at a current share price around US$61.86. The analysis highlights a divergence between short-term market sentiment and long-term valuation metrics, noting that while the stock has underperformed peers recently, historical 3 and 5-year returns remain positive at 21.9% and 57.0%, respectively. Recent coverage suggests the price drop is being weighed against broader healthcare trends and investor concerns regarding whether current prices reflect the company's position in the medical device space.
A Discounted Cash Flow (DCF) model conducted by Simply Wall St indicates that Boston Scientific may be undervalued, projecting an intrinsic value of approximately US$112.50 per share based on a 2 Stage Free Cash Flow to Equity model using inputs such as recent free cash flow of $3.63 billion and estimates reaching $6.84 billion by 2029. This projection implies a potential 45.0% discount compared to the current market price, suggesting the stock trades well below this calculated modelled value. The analysis also evaluates traditional metrics like Price-to-Earnings (P/E) ratios, where Boston Scientific currently trades at 31.7x, which is higher than the Medical Equipment industry average of 26.7x but lower than its peer group average of 40.9x, positioning it as more affordable relative to some direct competitors.
To further assess fair value, Simply Wall St employs a proprietary "Fair Ratio" methodology, estimating a reasonable P/E of 35.8x tailored to Boston Scientific's specific profile including earnings growth and market cap. Since the current P/E of 31.7x is below this Fair Ratio, the stock appears to be trading below this adjusted estimate as well. Beyond quantitative models, the article notes that qualitative "Narratives" from the Simply Wall St Community offer alternative valuation perspectives, with community member estimates ranging from US$80 to US$124 per share, reflecting varying degrees of optimism about future revenue and earnings potential. Ultimately, while the company faces valuation questions and recent headwinds, fundamental analysis using multiple methods suggests Boston Scientific could be trading at a significant discount to its calculated fair value, though this commentary is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell the stock.
π BSX shares fell 31.8% year-to-date, trading at $61.86 with a 45% discount to estimated value.
π° Strong historical returns (3Y: +21.9%, 5Y: +57.0%) and projected 2029 cash flow of $6.84B.
β Valuation sits at 31.7x P/E below Fair Ratio of 35.8x, though above industry average.
π Boston Scientific (BSX) shares have dropped 34.7% year-to-date and are currently trading around $61.86 per share.
π Over the past year, the stock has declined 31.8%, though it delivered positive 3-year (21.9%) and 5-year (57.0%) returns.
π° A Discounted Cash Flow model projects an intrinsic value of approximately $112.50 per share, implying a 45% discount to the current price.
π The company's latest twelve-month free cash flow was $3.63 billion, with estimates suggesting $6.84 billion in 2029.
π Boston Scientific trades at a P/E ratio of 31.7x, which is higher than the medical equipment industry average of 26.7x but lower than its peer group average of 40.9x.
βοΈ Simply Wall St's proprietary "Fair Ratio" for the company is set at 35.8x, indicating the stock trades below this tailored valuation estimate.
π§ The article highlights that different investor narratives might result in varying fair value targets, such as $80 or $124 per share.
π’ This analysis is based on historical data and analyst forecasts, with a disclaimer stating it does not constitute financial advice or a recommendation to buy or sell.
π₯ Boston Scientific's strong position in the medical device space is being weighed against current market sentiment and healthcare trends.
Bullish Signals
Intrinsic value of $112.50 per share, down 45% from recent price.
Fair Ratio suggests stock trades below tailored valuation estimates.
Strong future cash flow to $6.84 billion by 2029 projected.
Simply Wall St gives 5/6 score on value checks.
P/E of 31.7x is cheaper than peer average of 40.9x.
Risk Factors
Stock down 34.7% YTD and 31.8% over last year.
P/E of 31.7x above industry average of 26.7x.
Fair value uncertain between $80 and $124 per share.
Analysis may miss recent announcements or material factors.
Bullish Signals
Boston Scientific trades at an estimated intrinsic value of $112.50 per share according to the Discounted Cash Flow model, representing a 45.0% discount compared to its recent price of $61.86.
The company's proprietary 'Fair Ratio' of 35.8x suggests it is trading below its tailored valuation estimate given its earnings growth and risk profile.
Long-term free cash flow projections extend out to 2035 with extrapolated estimates suggesting $6.84b in cash flow by 2029, indicating strong future generating capacity.
Simply Wall St assigns a 5 out of 6 score on its value checks, highlighting positive fundamental metrics despite recent share price declines.
The current P/E ratio of 31.7x is below the peer group average of 40.9x, suggesting Boston Scientific may be relatively cheaper than some direct competitors.
Risk Factors
The stock has declined 34.7% year to date and 31.8% over the last year, indicating significant recent price weakness.
Current P/E of 31.7x sits above the Medical Equipment industry average of 26.7x, suggesting the stock appears expensive relative to sector peers despite being below the wider peer group average.
Valuation estimates vary significantly within investor community narratives, with fair value projections ranging from US$80 to US$124 per share, reflecting substantial uncertainty around intrinsic value.
The article explicitly states that analysis may not factor in the latest price-sensitive company announcements or qualitative material, potentially overlooking key negative catalysts.
Boston Scientific stock closed at $61.86, marking a 1.17% decline that lagged the broader S&P 500's modest 0.08% gain despite market fluctuations where the Dow lost 0.18% and Nasdaq rose 0.1%. The company has experienced a more pronounced 12.95% drop over the past month, significantly underperforming both the medical device sector, which fell 6.98%, and the overall S&P 500, which dropped 1.74% during the same period. Investors are closely monitoring the company ahead of its upcoming earnings disclosure scheduled for April 22, 2026, where analysts project an earnings per share of $0.8, representing a 6.67% growth over the equivalent quarter last year, and revenue estimates of $5.19 billion, an 11.2% increase from the prior-year quarter.
For the full fiscal year, Zacks Consensus Estimates anticipate Boston Scientific will report earnings of $3.45 per share and total revenue of $22.28 billion, reflecting projected growth rates of +12.75% and +10.99% respectively compared to the previous year. However, recent analyst estimate adjustments show a slight downward trend, with a 0.15% fall in the Zacks Consensus EPS estimate over the past month. Consequently, Boston Scientific currently holds a Zacks Rank of #3 (Hold). The article notes that while upward revisions often signal positive analyst sentiment and correlate with future stock price performance, the current data does not reflect such optimism. In terms of valuation metrics, the stock trades at a forward P/E ratio of 18.13, which is slightly below the industry average forward P/E of 18.15 for the medical products sector. Additionally, the company's PEG ratio stands at 0.97, significantly lower than the Medical - Products industry average of 1.59, suggesting the stock might be undervalued relative to its growth expectations compared to peers.
The broader market context highlights that the Medical - Products industry ranks in the bottom 34% of all industries according to the Zacks Industry Rank, which currently stands at 163 out of over 250 groups. Research indicates that top-performing industries tend to outperform the bottom half by a factor of 2 to 1, adding further context to Boston Scientific's recent performance. While the Zacks Rank #1 (Strong Buy) category has historically delivered an average annual return of +25% since 1988, Boston Scientific currently sits in a neutral holding zone. The article concludes by directing investors to utilize Zacks.com for real-time updates on these shifting metrics and suggests downloading their "7 Best Stocks for the Next 30 Days" report for additional investment recommendations.
π BSX stock fell 12.95% this month, trailing the broader S&P 500.
π° Analysts project quarterly revenue of $5.19B with an EPS of $0.8.
βοΈ Company trades at a forward P/E of 18.13, slightly below industry average.
π Boston Scientific (BSX) stock closed at $61.86, down 1.17%, trailing the S&P 500's gain and outperforming the Dow and Nasdaq mixed performance.
π₯ Over the past month, BSX shares have dropped 12.95%, which is a sharper decline than the Medical sector and the broader S&P 500 losses.
π Investors are anticipating the upcoming earnings report scheduled for April 22, 2026, with consensus estimates predicting an EPS of $0.8.
π Analyst forecasts suggest quarterly revenue will reach $5.19 billion, representing an 11.2% increase compared to the prior-year quarter.
π The annual forecast predicts earnings per share of $3.45 and revenue of $22.28 billion, with positive growth of 12.75% and 10.99% respectively.
βοΈ Boston Scientific is currently trading at a Forward P/E ratio of 18.13, which is slightly below its industry average of 18.15.
π The company has a PEG ratio of 0.97 compared to the Medical Products industry average of 1.59, suggesting a potentially attractive valuation relative to growth.
π₯ BSX holds a Zacks Rank of #3 (Hold), while the recent trend shows a slight 0.15% fall in the consensus EPS estimate over the past month.
π The Medical - Products industry is ranked in the bottom 34% of all industries with a Zacks Industry Rank of 163 out of over 250 sectors.
π‘ Zacks Investment Research notes that top-rated industries historically outperform bottom-tier groups by a factor of 2 to 1 based on research data.
Bullish Signals
EPS expected at $0.8, up 6.67% from last year.
Forecast annual revenue of $22.28 billion, a 10.99% increase.
Forward P/E of 18.13 is below the industry average of 18.15.
PEG ratio of 0.97 suggests value against industry average of 1.59.
Quarterly revenue estimated at $5.19 billion with 11.2% growth.
Risk Factors
Stock down 12.95% this month, underperforming sector and S&P 500.
Zacks Rank #3 (Hold) trails top stocks' +25% annual returns since 1988.
Industry ranks bottom 34%; top industries outperform bottom half by 2x.
PEG ratio of 0.97 is lower than industry average of 1.59.
The company is expected to post an EPS of $0.8, indicating 6.67% growth compared to the equivalent quarter last year.
Analysts are forecasting annual revenue of $22.28 billion, representing a 10.99% increase from the prior year.
Boston Scientific is trading at a Forward P/E ratio of 18.13, which is slightly below the industry average of 18.15, indicating a valuation discount.
The company's PEG ratio is 0.97, suggesting it is trading close to its expected earnings growth rate compared to the industry average of 1.59.
With an estimated upcoming revenue of $5.19 billion in the current quarter, Boston Scientific anticipates year-over-year growth of 11.2%.
Risk Factors
Boston Scientific's stock has dropped by 12.95% in the past month, significantly underperforming both the Medical sector's loss of 6.98% and the S&P 500's loss of 1.74%.
The company's Zacks Rank is #3 (Hold), which indicates neutral to negative sentiment compared to top-ranked stocks that deliver an average annual return of +25% since 1988.
The Medical - Products industry ranks in the bottom 34% of all industries according to its Zacks Industry Rank, with top-rated industries outperforming the bottom half by a factor of 2 to 1.
Boston Scientific's PEG ratio of 0.97 is significantly lower than the industry average PEG ratio of 1.59, potentially suggesting overvaluation relative to growth expectations or market skepticism.
Over the past month, there has been a 0.15% fall in the Zacks Consensus EPS estimate, indicating declining analyst confidence despite predicted earnings growth.
Large-cap stocks are currently facing significant selling pressure, according to analysis provided by Seeking Alpha. Nilanjana Basu, a SA News Editor, highlights that this trend is particularly evident in the healthcare, staples, and real estate sectors. The article identifies Sysco Corporation (NYSE SYY) and Boston Scientific Corporation (NYSE BSX) as the most oversold U.S. large-cap stocks based on Relative Strength Index (RSI) metrics. Specifically, Sysco has an RSI of 24, while Boston Scientific has an RSI of 25, positioning them at the lowest end of the list among major companies in these sectors.
Seeking Alpha's RSI screen flags stocks with a Relative Strength Index below 30 as potentially oversold, suggesting that high selling pressure may have pushed their valuations below fair value. This technical indicator is used to spot potential value plays for investors who believe the stocks could rebound once selling pressure subsides. Beyond Sysco and Boston Scientific, the report lists nine other large-cap names in health care, staples, and real estate that also appear on the oversold list, indicating a broader trend of market correction in these specific industries during the current market environment.
The article frames this analysis as part of an effort to bridge the gap between financial information and actionable insight for investors. By focusing on sectors including healthcare, consumer staples, and real estate, the report aims to help investors identify companies that might be undervalued relative to their peers. The data is presented within Seeking Alpha's broader research platform, which provides Quant ratings and market-beating analysis tools to support investment decisions. This summary reflects the information available as of April 1, 2026, when the news was published on Seeking Alpha.
π Sysco (24) and Boston Scientific (25) rank as most oversold large-caps by RSI metrics.
π‘ Ten undervalued stocks identified across healthcare, staples, and real estate sectors.
π¨ Low RSI indicates potential rebound but requires fundamental analysis confirmation.
π Sysco Corporation (SYY) and Boston Scientific Corporation (BSX) are identified as the most oversold U.S. large-cap stocks based on Relative Strength Index (RSI) metrics.
π’ SYY currently has an RSI of 24, while BSX has an RSI of 25, both falling significantly below the typical 30 threshold for oversold conditions.
π₯ Boston Scientific operates within the healthcare sector, whereas Sysco is a leading distributor within the consumer staples industry.
π The article presents a list of ten large-cap stocks with low RSI signals across sectors including health care, staples, and real estate.
π‘ Analysts suggest that an RSI below 30 may indicate high selling pressure, potentially creating opportunities for value investors to consider buying.
β οΈ These findings come amid broader market trends where large-cap stocks are experiencing significant selling pressure.
π’ Other companies on the oversold watchlist include Omega Healthcare Investors, Lennar Corporation, and McCormick & Company.
π The analysis uses RSI data as a key technical indicator to screen for undervalued opportunities in established companies.
π¬ The content is published by Seeking Alpha's Nilanjana Basu on April 1, 2026, targeting investors looking for value plays in specific sectors.
π Investors may view these low RSI stocks as potential rebound candidates if market sentiment shifts positively.
π¨ While low RSI suggests potential value, it does not guarantee an immediate price increase and should be analyzed alongside other fundamentals.
Bullish Signals
Sysco and Boston Scientific are oversold U.S. large-cap value opportunities.
Both stocks have RSI values of 24 and 25, well below the 30 threshold.
Low RSI suggests these names are undervalued due to selling pressure.
The analysis covers health care, staples, and real estate sectors.
Boston Scientific shows strong potential within the health care sector.
Risk Factors
Sysco RSI at 24 shows extreme oversold conditions.
Boston Scientific RSI at 25 reflects severe selling pressure.
Sysco and Boston Scientific are identified as the most oversold U.S. large-cap stocks, indicating potential value opportunities after significant selling pressure.
Both Sysco (SYY) and Boston Scientific (BSX) have Relative Strength Index (RSI) values of 24 and 25 respectively, which is below the traditional 30 threshold that signals oversold conditions.
An RSI reading below 30 suggests these large-cap names may be undervalued due to excessive selling pressure, positioning them as attractive value plays for investors.
The analysis covers key sectors such as health care, staples, and real estate, with Boston Scientific representing the strong performance potential within the health care sector.
Identifying top 10 large-cap stocks ranked by their RSI signals provides a clear framework for spotting potential rebounds in established market leaders.
Risk Factors
Sysco's Relative Strength Index (RSI) has fallen to 24, indicating extreme oversold conditions that may signal continued weakness or lack of recent buying interest.
Boston Scientific's RSI stands at 25, reflecting similar severe selling pressure as the second-most depressed large-cap stock on the list.
The article highlights that these stocks are under significant selling pressure, suggesting that recent price declines have eroded investor confidence despite being flagged as 'value plays'.
Boston Scientific CEO Mike Mahoney saw his total annual compensation rise to $23.5 million in 2025, marking an increase of over $2 million from the previous year and continuing a trend that has pushed executive pay above the $20 million threshold for the first time since 2009. The Massachusetts-based medical device manufacturer also reported robust financial performance for the period, with revenue reaching $20.1 billion in 2025, representing a 20% increase year-over-year. Alongside rising executive pay, the company disclosed that median employee compensation grew by double digits during the same timeframe, which Mahoney attributed to the companyβs focus on relentless innovation and consistent financial growth aimed at sustaining long-term leadership in the medtech sector.
Mahoneyβs specific 2025 compensation package was detailed as consisting of a $1.44 million salary, $13.6 million in stock awards, $3.8 million in option awards, and a $4 million cash bonus. Additional benefits included a change in pension value of $441,611, other compensation totaling $287,799 (covering 401(k) matches and insurance), and personal use of the corporate aircraft valued at up to $225,000 for the year, an increase of $75,000 from 2024. This package represented a 10% rise over his prior yearβs compensation. The company justified part of the aircraft cost increase by citing evolving security and travel considerations for senior executives approved by the Compensation Committee.
Key executive officers also received substantial raises that reflected broader shifts in leadership and organizational structure. EVP and Cardiovascular Group President Joe Fitzgerald saw his total pay jump 27% to $8 million, while EVP and MedSurg and Asia Pacific Group President Art Butcher experienced a compensation increase of more than 30%, totaling $6.5 million. In finance leadership, former CFO Daniel Brennan retired in June 2025 after over 30 years with the company, having earned $6.3 million in his final year, while his successor Jon Monson received $6.1 million for the same period. Other executives including former EVP Jeff Mirviss and SVP Vance Brown also reported compensation figures ranging from $3.9 million to $4.2 million, with several retiring or transitioning roles at the end of 2025.
π Revenue surged 20% to $20.1B in 2025, a record high.
π° CEO pay exceeded $23.5M for the first time since 2009.
β Executive aircraft use rose due to enhanced security needs.
π’ Boston Scientific reported $20.1 billion in revenue for 2025, representing a 20% year-over-year increase.
π° CEO Mike Mahoney's total compensation exceeded $23.5 million in 2025, surpassing the $20 million mark for the first time since 2009.
π Mahoney's pay represents more than a $2 million increase from the previous year, driven by stock and option awards.
βοΈ The CEO received $225,000 in annual corporate aircraft personal use value, an increase of $75,000 due to security considerations.
π₯ Median employee pay at Boston Scientific also increased by double digits during the 2025 fiscal year.
πΌ Executive Vice President Joe Fitzgerald earned $8 million total compensation, a 27% rise from the prior year.
π€ EVP Art Butcher received $6.5 million in total pay, with his overall compensation rising over 30% year-over-year.
πΆ Daniel Brennan retired after 30 years at the company, receiving $6.3 million in final compensation before his departure.
πΌ New CFO Jon Monson joined the leadership team and received $6.1 million in total compensation for 2025.
π΄ EVP Jeff Mirviss retired at the end of 2025 with a total compensation package of $4.2 million, a 3% increase from the previous year.
βοΈ The Compensation Committee approved Mahoney's aircraft allocation increase after reviewing evolving security and travel requirements for senior executives.
π CEO Mahoney emphasized that the company remains focused on strengthening its innovation ecosystem and differentiated product pipeline.
Bullish Signals
Revenue grew 20% year-over-year to $20.1B.
CEO compensation exceeded $23.5 million for first time since 2009.
Median employee pay rose double digits in 2025.
Management focuses on innovation ecosystem and sustainable growth.
CFO Jon Monson ensures continuity after 30 years.
Bullish Signals
Revenue grew 20% year-over-year to $20.1 billion in 2025, marking strong financial performance.
CEO Mike Mahoney's total compensation exceeded $23.5 million, surpassing the $20 million mark for the first time since 2009, reflecting the company's high value proposition for leadership.
Median employee pay rose by double digits in 2025, indicating significant investment in talent and competitive compensation standards.
Management continues to focus on strengthening its innovation ecosystem with a differentiated product pipeline designed for sustainable long-term growth.
CFO Jon Monson replaced outgoing CFO Daniel Brennan after over 30 years, ensuring continuity of leadership in financial operations.
Executive turnover at the highest levels appears orderly, with former leaders retiring smoothly and new executives like Jon Monson ready to step into key roles.
Risk Factors
CEO Mike Mahoney's annual compensation exceeded $23.5 million in 2025, representing an increase of over $2 million and breaking the $20 million barrier for the first time since Ray Elliott received $33.5 million in 2009.
Median employee pay also rose by double digits in 2025, widening the compensation gap between executives and regular staff despite claims of 'relentless innovation'.
The company approved a significant increase in personal use of corporate aircraft for CEO Mike Mahoney to $225,000 per year, up from $150,000, raising questions about executive perks versus shareholder value.
CVP and MedSurg President Art Butcher's total compensation rose by more than 30% year-over-year, while EVP and CFO Jon Monson received a higher base salary adjustment compared to his predecessor Daniel Brennan who retired with $6.7 million pay.
Former Peripheral Interventions President Jeff Mirviss retired at the end of 2025 after receiving $4.2 million in total compensation, suggesting high turnover or restructuring costs within specific business units.
The article notes that while revenue grew 20%, the focus on executive and median pay raises does not directly correlate to improved operational efficiency or profitability metrics.
Truist Financial recently lowered its price target on Boston Scientific Corporation (NYSE:BSX) from $95 to $92 while reaffirming its Buy rating. This adjustment occurred on March 18 ahead of a key clinical trial readout for the CHAMPION-AF procedure, which Truist expects will yield positive data at endpoints and potentially expand the FDA-approved indication for their WATCHMAN left atrial appendage occluder device. Concurrently, UBS also downgraded its price target on the same stock to $105 from $120 on March 17, though they maintained a Buy rating.
Boston Scientific reported strong financial performance in fiscal Q4 and full year 2025. For the quarter, net sales reached $5.286 billion, representing a 15.9% increase on a reported basis, 14.3% growth operationally, and 12.7% organic growth compared to the prior year. Full year 2025 results showed net sales of $20.074 billion, marking a 19.9% reported increase, 19.2% operational growth, and 15.8% organic expansion. The company continues its focus on interventional medical procedures through its Cardiovascular segment (covering Cardiology and Peripheral Interventions) and MedSurg segment (including Urology, Endoscopy, and Neuromodulation).
The article concludes with a separate recommendation from the publication suggesting readers consider AI stocks over Boston Scientific for greater upside potential and less downside risk, specifically noting benefits from potential Trump-era tariffs and onshoring trends. This section serves as promotional content directing readers to free reports on other equities rather than additional analysis of Boston Scientific itself. The core investment updates regarding price targets and financial results remain the central focus of the piece.
π Analysts lowered Boston Scientific price targets to $92β$105 despite Buy ratings.
π Q4 net sales hit $5.29B with 15.9% growth and 12.7% organic increase.
π Positive CHAMPION-AF data could expand the WATCHMAN device indication.
π Truist lowered its price target on Boston Scientific Corporation (BSX) from $95 to $92 while maintaining a Buy rating.
π UBS cut its price target for BSX from $120 to $105 but reiterated its Buy recommendation.
π Analysts expect positive trial data for the CHAMPION-AF readout, which could lead to an expanded WATCHMAN indication.
π Boston Scientific reported Q4 2025 net sales of $5.286 billion, representing a 15.9% growth on a reported basis.
π For full year 2025, the company generated net sales of $20.074 billion, up 19.9% on a reported basis.
βοΈ The company's operations are divided into two main segments: Cardiovascular and MedSurg.
β€οΈ The Cardiovascular segment covers Cardiology and Peripheral Interventions.
πͺ The MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
β οΈ One analyst note suggests AI stocks may offer greater upside potential and less downside risk compared to BSX.
πΊπΈ Some commentary highlights the benefits of AI stocks from Trump-era tariffs and onshoring trends.
π Organic sales growth for Q4 2025 was reported at 12.7%.
πΏ Organic sales growth for full year 2025 was reported at 15.8%.
Bullish Signals
Truist and UBS maintain Buy ratings on Boston Scientific (NYSE: BSX).
Q4 net sales reached $5.286 billion, up 15.9% year-over-year.
Full year 2025 revenue hit $20.074 billion.
CHAMPION-AF device trials could expand WATCHMAN indications.
Diversified segments span Cardiovascular, MedSurg, Urology, and Neuromodulation.
Risk Factors
Truist cuts BSX target to $92 despite Buy rating.
UBS slashes BSX target to $105 citing valuation concerns.
AI stocks offer greater upside than Boston Scientific.
Investors prefer AI gains from Trump tariffs over BSX.
Capital flight to AI sectors suppresses BSX valuation.
Bullish Signals
Truist and UBS both maintain a Buy rating on Boston Scientific (NYSE: BSX), demonstrating continued institutional confidence in the stock despite price target adjustments.
Boston Scientific reported strong financial growth with Q4 net sales of $5.286 billion, representing a 15.9% increase compared to the prior year.
The company's full year 2025 revenue reached $20.074 billion, which is up nearly 20% on a reported basis and 15.8% on an organic basis.
Investors anticipate positive trial data for the CHAMPION-AF device that could lead to an expanded indication for the WATCHMAN technology.
The firm's diversified operations across Cardiovascular and MedSurg segments, including Urology, Endoscopy, and Neuromodulation, provide broad market exposure.
Risk Factors
Truist analysts cut the price target on Boston Scientific (BSX) from $95 to $92, downgrading expectations for the stock despite reiterating a Buy rating.
UBS also reduced its price target on BSX significantly from $120 to $105 on March 17, indicating concern over valuation or alternative opportunities.
The Truist analyst note explicitly states that other AI stocks offer greater upside potential and carry less downside risk than Boston Scientific.
Truist suggests investors might find more attractive short-term gains in undervalued AI stocks benefiting from Trump-era tariffs rather than in medical device manufacturers.
Investor sentiment is being diverted away from BSX toward competing sectors like artificial intelligence, potentially suppressing long-term valuation support.
Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX) concerning alleged misrepresentations regarding its U.S. Electrophysiology segment disclosures. Plaintiffs assert that the company misled investors about growth prospects and competitive threats within this business line, claims which emerged following disappointing financial results and updated guidance that highlighted ongoing pressures in the sector. The legal actions specifically target how company leadership communicated business fundamentals and long-term growth sustainability, drawing scrutiny to whether public statements aligned with underlying operational performance in a key segment closely watched by investors.
The litigation introduces additional layers of risk involving potential legal expenses, management distraction, and reputational harm that could influence market sentiment beyond standard operating results. Analysts at Simply Wall St note that Boston Scientific shares are currently trading at US$69.13, approximately 33% below the consensus analyst target of US$103.82 and roughly 21.7% below an estimated fair value. The stock has experienced a 30-day return decline of about 7.5%, reflecting recent market pressure that correlates with the legal headlines surrounding the company's Electrophysiology business communications.
Investors are advised to monitor the progression of these class action cases, watch for any financial restatements or updated guidance specific to the U.S. Electrophysiology segment, and observe how management addresses competitive pressures in future communications. The primary risk highlighted is that prolonged litigation could negatively impact reputation and legal costs, potentially weighing on investor interpretation of future disclosures even if no fundamental structural issues are immediately identified. Simply Wall St emphasizes that their analysis does not constitute financial advice and that their commentary is based on historical data and analyst forecasts without a position in the stock mentioned.
β Multiple lawsuits allege Boston Scientific misled investors regarding U.S. Electrophysiology disclosures.
πΈ Legal risks include high costs, reputation damage, and diversion of management focus.
π Stock trades at a 33% discount to analyst targets amid recent market decline.
βοΈ Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX) regarding disclosures about its U.S. Electrophysiology segment.
π Plaintiffs allege the company misled investors by overstating growth prospects and underestimating competitive threats within this business line.
π The legal challenges follow disappointing financial results and guidance that highlighted significant pressures in the Electrophysiology sector.
π Legal claims center on misrepresentations made by company leadership concerning business fundamentals and long-term sustainability of growth.
πΌ Boston Scientific operates across various medical technology segments, with the U.S. Electrophysiology unit being a key focus for investors scrutinizing management communication.
βοΈ The lawsuits highlight the connection between public statements and the underlying performance of this critical segment of the company.
π Investors will closely monitor the legal cases' progress, emerging disclosures, and how management addresses these allegations publicly.
πΈ These suits introduce additional risks related to potential legal costs, diversion of management time, and potential reputational damage.
π Stock price analysis shows shares trading at US$69.13 against an analyst consensus target of US$103.82, representing a 33% discount.
βοΈ Simply Wall St's valuation suggests shares are approximately 21.7% below their estimated fair value, potentially exacerbated by lawsuit-related sentiment.
π Recent momentum shows a 30-day decline of about 7.5%, correlating with the negative impact of these legal headlines on the market.
β οΈ Key risk factors include prolonged litigation affecting reputation and financial health, even if no structural business risks are currently flagged.
π Future investor attention will focus on financial restatements, updated guidance for the U.S. Electrophysiology segment, and competitive pressure updates.
π This article is provided by Simply Wall St as general commentary and does not constitute specific financial advice or a recommendation to buy or sell BSX shares.
Bullish Signals
Price sits 33% below analyst consensus targets.
Simply Wall St shows 21.7% downside to fair value.
30-day decline suggests recent legal pressure is temporary.
Diversified medical tech segments reduce reliance on EP.
Risk Factors
Litigation raises integrity concerns over EPS segment disclosures.
Leaders allegedly misled investors on growth prospects.
Disappointing results compound negative outlook amid lawsuits.
Stock trades 33% below analyst target at $69.13.
Skepticism widens gap as sentiment deteriorates further.
Bullish Signals
At US$69.13 against a consensus target of US$103.82, the price sits roughly 33% below where analysts expect it to be, offering significant upside potential.
Simply Wall St Valuation shows shares are trading about 21.7% below an estimated fair value, which may matter if the lawsuits affect sentiment more than fundamentals.
The 30 day return of about 7.5% decline shows recent pressure that lines up with the legal headlines, suggesting current price weakness could be temporary.
Boston Scientific operates across several medical technology segments, diversifying risk beyond just the U.S. Electrophysiology business under scrutiny.
Risk Factors
Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX) specifically over disclosures about its U.S. Electrophypiology segment, raising concerns about management integrity and investor trust.
The legal claims allege that company leadership misled investors regarding growth prospects and competitive threats in the Electrophysiology business line, suggesting potential misrepresentation of fundamentals.
Boston Scientific recently reported disappointing financial results and guidance that explicitly highlighted ongoing pressures within the Electrophysiology segment, compounding the negative outlook amid litigation.
At US$69.13, the stock price sits roughly 33% below the consensus analyst target of US$103.82, indicating significant market skepticism about current valuation and future prospects.
Simply Wall St estimates shares are trading about 21.7% below an estimated fair value, a gap that could widen if lawsuit-related sentiment continues to deteriorate.
The stock has experienced a 30-day return decline of approximately 7.5%, reflecting recent price pressure that correlates directly with the negative legal headlines.
Prolonged litigation exposes the company to significant downstream risks including increased legal costs, distraction of management time, and potential reputational damage that could affect future disclosures.
Rosen Law Firm has announced a securities class action lawsuit on behalf of investors in Boston Scientific Corporation (NYSE: BSX) alleging securities fraud within the company's electrophysiology segment. The firm asserts that between July 23, 2025 and February 3, 2026, defendants made positive statements while concealing material adverse facts about the true state of the business, specifically noting management's awareness that the segment's growth rate was unsustainable and approaching an earlier tipping point than anticipated. According to the complaint, these misleading statements led investors to suffer financial damages after Boston Scientific released a net income miss and underwhelming guidance for the first half of fiscal 2026, causing stock prices to react negatively once the true details entered the market.
Investors who purchased common stock during this class period are invited to submit a claim by filling out a form on the law firm's website or contacting attorney Phillip Kim directly. Rosen Law emphasizes that joining the action incurs no out-of-pocket fees or costs, as they operate under a contingency fee arrangement. While the firm encourages investors to select qualified counsel with a proven track record, it clarifies that a class has not yet been certified by the court and that an investor's ability to share in any potential recovery is not dependent on serving as lead plaintiff. Interested parties wishing to serve as lead plaintiff must move the Court no later than May 4, 2026, whereas absent members can choose to do nothing or retain independent counsel if desired.
β Rosen Law seeks lead plaintiff by May 4, 2026.
π° Investors join for free via contingency fee arrangements.
π Lawsuit alleges fraud over Boston Scientific's weak 2026 guidance.
π Rosen Law Firm announces a class action lawsuit on behalf of Boston Scientific Corporation (BSX) shareholders regarding potential securities fraud.
β³ The lawsuit covers stock purchases made between July 23, 2025 and February 3, 2026.
π₯ Investors can join the existing suit for free through a contingency fee arrangement without upfront costs.
βοΈ Those wishing to serve as lead plaintiff must file a motion with the court by May 4, 2026.
π Interested parties may submit forms via the firm's website or contact Phillip Kim, Esq., directly.
β οΈ The complaint alleges defendants made misleading statements while concealing issues within Boston Scientific's U.S. Electrophysiology segment.
π Plaintiffs claim management knew growth rates were unsustainable and that the business faced an earlier tipping point than anticipated.
πΈ Investors allegedly suffered financial damage when the market reacted to Boston Scientific's net income miss and weak guidance for fiscal 2026.
β οΈ No class has been certified yet, meaning investors are not automatically represented and may choose their own counsel.
π Rosen Law Firm cites its history of large settlements and top rankings in securities class action litigation as a key differentiator.
π’ The firm is seeking to recruit qualified leadership for the case, noting that many firms lack comparable resources or experience.
Bullish Signals
Secured over $438 million in recoveries alone in 2019.
Ranked No. 1 for settlements in 2017.
Remained in top 4 annually since 2017.
Risk Factors
Unsustainable U.S. Electrophysiology growth threatens long-term revenue viability.
Management accused of concealing adverse facts and transparency issues.
Net income miss and weak fiscal 2026 guidance disappoint investors.
Securities fraud lawsuit filed for stock purchases between July 23, 2025 and February 3, 2026.
False statements risk regulatory scrutiny, reputational damage, and costly settlements.
Bullish Signals
Rosen Law Firm has a proven track record of success, having secured over $438 million in investor recoveries alone in 2019.
The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and remained in the top 4 each year since then.
Risk Factors
The lawsuit alleges that Boston Scientific's U.S. Electrophysiology segment growth rate was unsustainable and approaching an earlier tipping point than the market anticipated, raising concerns about the long-term viability of this revenue driver.
Management is accused of making positive statements while simultaneously concealing material adverse facts concerning the true state of the business, suggesting potential internal governance or transparency issues.
Investors were reportedly left surprised by Boston Scientific's net income miss and underwhelming guidance for the first half of fiscal 2026, indicating a possible disconnect between management's public outlook and actual operational performance.
A securities fraud class action lawsuit has been filed regarding stock purchases between July 23, 2025 and February 3, 2026, signaling significant investor dissatisfaction and potential financial liabilities for the company.
The legal claim posits that defendants disseminated materially false and misleading statements, which could lead to severe regulatory scrutiny, reputational damage, and costly settlements if proven in court.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)